Tumor renal benigno versus carcinoma renal: reporte de caso y revisión de la literatura

Tumor renal benigno versus carcinoma renal: reporte de caso y revisión de la literatura

Resumen Introducción El cáncer renal representa 2,4% de los casos diagnosticados de cáncer en la población general, es más común en hombres que en mujeres, y se presenta con más frecuencia entre la 6ta y la 8ta décadas de vida. Se estima que el 16% de los pacientes se diagnostican como...

Full description

Bibliographic Details
Main Authors:	Jorge Enrique Salinas Perdomo, Ángela Luna Meza, Camilo Castañeda-Cardona, Diego Rosselli
Format:	Article
Language:	English
Published:	Thieme Revinter Publicações 2019-03-01
Series:	Urología Colombiana
Subjects:	diagnóstico diferencial neoplasias renales carcinoma de células renales angiomiolipoma sunitinib pazopanib axitinib bevacizumab
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1656553

Similar Items

Pazopanib in the treatment of advanced renal cell carcinoma
by: M. I. Volkova, et al.
Published: (2018-11-01)

Neoadjuvant targeted therapy in patients with renal cell carcinoma
by: B. Ya. Alekseev, et al.
Published: (2015-06-01)

Sorafenib is the first targeted agent to treat metastatic kidney cancer
by: V. B. Matveev, et al.
Published: (2015-03-01)

Sorafenib is the first targeted agent to treat metastatic kidney cancer
by: V. B. Matveev, et al.
Published: (2015-03-01)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
by: Jun Guo, et al.
Published: (2018-05-01)

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
by: Gaetano Facchini, et al.
Published: (2019-08-01)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
by: Xinan Sheng, et al.
Published: (2020-03-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry
by: Radek Lakomy, et al.
Published: (2017-12-01)

Angiomiolipoma renal: presentación de cuatro casos
by: Edwin Cagua Agudelo, et al.
Published: (1994-04-01)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
by: Nanna Bæk Møller, et al.
Published: (2019-09-01)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
by: Fiala O, et al.
Published: (2021-05-01)

Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
by: Huan Deng, et al.
Published: (2019-05-01)

Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma
by: B. Ya. Alekseev, et al.
Published: (2018-07-01)

Pazopanib-induced alopecia, an underestimated toxicity?
by: Andrea eBiondo, et al.
Published: (2015-05-01)

Renal angiomyolipoma
by: Selahattin Çalışkan, et al.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
by: Asim Amin, et al.
Published: (2018-10-01)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
by: Sylvie Négrier, et al.
Published: (2017-08-01)

Clinical and economic analysis of the 1st and 2nd target lines
by: I. N. D’yakov, et al.
Published: (2016-12-01)

The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
by: B. Ya. Alekseev, et al.
Published: (2021-06-01)

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol
by: Guillaume Mouillet, et al.
Published: (2019-02-01)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
by: Chau V, et al.
Published: (2020-08-01)

Multicentric angiomyolipoma in kidney, liver, and lymph node: case report/review of the literature
by: Artur S. de Azevedo, et al.
Published: (2015-06-01)

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
by: Koutsoukos K, et al.
Published: (2017-10-01)

Angiomiolipoma renal con invasión de vena renal y vena cava inferior. Presentación de un caso y revisión de la literatura
by: Garazi Gutiérrez-Zurimendi, et al.
Published: (2020-03-01)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
by: Kazuyuki Numakura, et al.
Published: (2021-09-01)

Axitinib in metastatic renal cell carcinoma: single center experience
by: Agnieszka Buraczewska, et al.
Published: (2017-01-01)

Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib
by: Takashi Kawahara, et al.
Published: (2019-07-01)

Síndrome de Wunderlich, uma causa rara de dor abdominal
by: Pedro Oliveira, et al.
Published: (2017-12-01)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
by: Ibon Gurruchaga Sotés, et al.
Published: (2021-06-01)

The world of targeted therapies in kidney cancers: pitfalls, tips and tricks
by: Vallard A, et al.
Published: (2017-03-01)

Prognostic factors of the therapeutic efficacy of mTOR and VEGFR inhibitors in patients with metastatic renal cell carcinoma
by: Е. А. Voroshilova, et al.
Published: (2015-12-01)

Axitinib in sequential therapy in metastatic renal cell carcinoma
by: Agata Kuchar, et al.
Published: (2015-05-01)

Papillary Renal Cell Carcinoma Presenting as a Perinephric Abscess
by: Vinod Kumar, et al.
Published: (2018-04-01)

Clinical economic assessment of the use of pazopanib in the therapy of disseminated kidney cancer
by: S. K. Zyryanov, et al.
Published: (2016-05-01)

Brazilian data of renal cell carcinoma in a public university hospital
by: Pedro Aguiar Junior, et al.
Published: (2016-02-01)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
by: Que Y, et al.
Published: (2018-07-01)

Gallbladder Metastasis from Renal Cell Carcinoma
by: Takashi Kawahara, et al.
Published: (2010-01-01)

Delayed nivolumab‐induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: An autopsy case
by: Maki Todo, et al.
Published: (2019-09-01)

Recommendations for the management of renal involvement in tuberous sclerosis complex
by: Gema Ariceta, et al.
Published: (2020-03-01)

Cannot write session to /tmp/vufind_sessions/sess_kli6iflpmfor2r91d9imd22m3t